Current approaches to potential amyloid-based Alzheimer's disease therapies: Defeating dementia

Ayesha Khan, Clive Ballard

Research output: Contribution to journalReview articlepeer-review

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, accounting for 700000 people in the UK and 25 million people worldwide with dementia1. Already licensed treatments, cholinesterase inhibitors and an NMDA (N-methyl-d-aspartate) receptor antagonist, confer important symptomatic benefits2, but at present, there are no treatments that can delay or halt the disease progression. This review outlines one of the main mechanisms currently thought to underpin the development of AD, and the treatments that are being developed based upon it.

Original languageEnglish (US)
Pages (from-to)14-17
Number of pages4
JournalBiochemist
Volume30
Issue number5
DOIs
StatePublished - Oct 2008

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Neurotransmitters
  • Statins
  • β-amyloid plaque
  • β-secretase
  • γ-secretase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Current approaches to potential amyloid-based Alzheimer's disease therapies: Defeating dementia'. Together they form a unique fingerprint.

Cite this